anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a mono-center, observational, controlled study with 2 parallel groups (obese versus non-obese pregnant women). The study will be conducted at the University Hospital of Basel, Department of Obstetrics and Antenatal Care. A total of N=188 healthy pregnant women (expected 40% with BMI ≥ 30 kg/m2) will be recruited in the first trimester in our outpatients' department in order to have a total of 169 evaluable women, considering a drop-out rate of 10%. Serum hepcidin, iron and hematological parameters will be measured at 11-14, 24-28, 32-36 weeks of gestation and at labor. The blood pressure, weight, weight gain, BMI and smoking status will be examined at all visits. Blood samples will be measured in the University Hospital of Basel, Department of Laboratory Medicine. Recruitment will begin in January 2019.
Arboviral epidemics continue to emerge suddenly and spread of disease is unpredictable. The 2015-16 Zika epidemic resulted in a high case number in Thailand, but not in neighboring Cambodia. It is known that nonhuman primates (NHPs) are important reservoirs of arboviruses, but the importance of their epidemiological role in the transmission of arboviruses is not clearly understood. While transmission dynamics are complex and require consideration of many variables, primate reservoirs are not routinely sampled, particularly in Southeast Asia, because of the level of operational complexity and skill required.

Here, we propose a serological survey for evidence of Zika virus (ZIKV), dengue virus (DENV), and chikungunya virus (CHIKV) exposure in long-tailed macaques and human adults who live or work in close proximity to these monkeys in Thailand and Cambodia. We hypothesize that ZIKV seroprevalence in both humans and macaques will be higher in Thailand than Cambodia. With the current rise of arboviral diseases around the world, we hope the results of this study contribute to better understanding of the epidemiology and burden of arboviral diseases in this region.
BACKGROUND: Avascular necrosis (AVN) of the humeral head is characterized by osteonecrosis secondary to disrupted blood flow to the glenohumeral joint. Following collapse of the humeral head, arthroplasty, namely, total shoulder arthroplasty (TSA) or humeral head arthroplasty (hemiarthroplasty), is recommended standard of care. The literature is limited to underpowered and small sample sizes in comparing arthroplasty modalities. Therefore, the aims of this study were (1) to compare the 10-year survivorship of TSA and hemiarthroplasty in the treatment of AVN of the humeral head and (2) to identify differences in their revision etiologies.
METHODS: Patients who underwent primary TSA and hemiarthroplasty for AVN were identified using the PearlDiver database. TSA patients were matched by age, gender, and Charlson Comorbidity Index (CCI) to the hemiarthroplasty cohort in a 4:1 ratio because TSA patients were generally older, sicker, and more often female. The 10-year cumulative incidence rate of all-cause revision was determined using Kaplan-Meier survival analysis. Multivariable analysis was conducted using Cox proportional hazard modeling. χ2 analysis was conducted to compare the indications for revisions between matched cohorts including periprosthetic joint infection (PJI), dislocation, mechanical loosening, broken implants, periprosthetic fracture, and stiffness.
RESULTS: In total, 4825 patients undergoing TSA and 1969 patients undergoing hemiarthroplasty for AVN were included in this study. The unmatched 10-year cumulative incidence of revision for patients who underwent TSA and hemiarthroplasty was 7.0% and 7.7%, respectively. The matched 10-year cumulative incidence of revision for patients who underwent TSA and hemiarthroplasty was 6.7% and 8.0%, respectively. When comparing the unmatched cohorts, TSA patients were at significantly higher risk of 10-year all-cause revision (HR: 1.39; P = .017) when compared to hemiarthroplasty patients. After matching, there was no significant difference in risk of 10-year all-cause revision (HR: 1.29; P = .148) and no difference in the observed etiologies for revision (P > .05 for all).
CONCLUSION: After controlling for confounders, only 6.7% of TSA and 8.0% hemiarthroplasties for humeral head AVN were revised within 10 years of index surgery. The demonstrated high and comparable long-term survivorship for both modalities supports the utilization of either for the AVN induced humeral head collapse.
FIELD: medicine, allergology. SUBSTANCE: invention relates to method of preparing allergens in aim of their following using for detection of allergic response of patient in professional trail selection. Method involves the development of preparing industrial allergen by extraction of air pollutants in industrial compartment. Taking away air is passed successively through two Bobrov's devices containing 70% ethyl alcohol. Mixture is shaken, centrifuged, dried and obtained precipitated is defatted with, for example, ether followed by dilution of allergen with standard dilution liquid. EFFECT: expanded assortment of measures for control of allergic diseases. 3 cl, 1 dwg
The disclosure provides programmable methylation "writers" and demethylation "erasers" for editing the methylation state of RNA targets, e.g., an RNA transcriptome. In particular, the disclosure provides RNA methylation editor polynucleotide contructs and vectors comprising (i) an RNA programmable RNA binding domain (RNApRNAbd); and (ii) an effector domain, wherein the effector domain is capable of adding or removing a methyl group in an RNA. The disclosed RNA methylation editor constructs are capable of achieving limited off- target modifications in RNA molecules. Further, the disclosure provides methods for making and using the programmable methylation editors to modifying the methylation state of RNA. The disclosure further provides complexes comprising a methylation writer protein and a guide RNA molecule and complexes comprising a demethylation eraser protein and a guide RNA molecule. The disclosure further provides pharmaceutical compositions and cells comprising the disclosed fusion proteins and complexes.
BACKGROUND AND STUDY AIM: Data from the AWARE study (A Worldwide Antihistamine-Refractory chronic urticaria patient Evaluation) illustrate a substantial disease burden in German patients with H1-antihistamine (-H1-AH)-refractory chronic spontaneous urticaria (CSU). Detrimental effects on patients' quality of life, poor disease control and impairment in the ability to work and perform other daily activities are reported. Based on these findings, this study aims to quantify the epidemiological and socio-economic burden of H1-AH-refractory CSU in Germany.
METHODS: To determine the epidemiological burden of H1-AH-refractory CSU, the age- and gender-specific prevalence of CSU and the proportion of H1-AH-refractory patients in Germany anonymized data from the InGef research database have been used. In a second step, the socio-economic burden in terms of lost numbers of hours in paid and unpaid work was calculated by extrapolating the age- and gender-specific work productivity and activity impairment (WPAI) observed in AWARE to the H1-AH-refractory CSU population in Germany. Finally, productivity losses in paid and unpaid work were monetized using the human capital and the friction cost approach respectively. Moreover, socio-economic burden was calculated depending on symptom control of the patients (measured by urticaria control test [UCT]).
RESULTS: In Germany, over 203,000 patients (20 years or older) had H1-AH-refractory CSU in 2018. The avoided lost paid and unpaid work hours attributable to H1-AH-refractory CSU summed up to over 100 million. Overall, the socio-economic burden of H1-AH-refractory CSU in monetary terms was evaluated at € 2.2 billion and the majority of this was due to unpaid work loss. Patients with poor disease control, as indicated by UCT score < 12, were more likely to suffer from high impairment than patients with controlled disease, resulting in a higher socio-economic burden.
CONCLUSIONS: The results of our analyses picture the substantial socio-economic burden of H1-AH-refractory CSU and therefore the tremendous impact it has on daily lives of individuals and society overall.
Doxazosin works on a specific type of muscle found in the prostate, causing it to relax. This in turn decreases the pressure within the prostate, thus improving the flow of urine and your symptoms.

  * Doxazosin Tablets help relieve the symptoms of BPH (weak stream, start-and-stop stream, a feeling that your bladder is not completely empty, delay in beginning of urination, need to urinate often during the day and especially at night, and feeling that you must urinate immediately). It does not change the size of the prostate. The prostate may continue to grow; however, a larger prostate is not necessarily related to more symptoms or to worse symptoms. Doxazosin Tablets can decrease your symptoms and improve urinary flow, without decreasing the size of the prostate.
  * If Doxazosin Tablets are helping you, you should notice an effect within 1 to 2 weeks after you start your medication. Doxazosin Tablets have been studied in over 900 patients for up to 2 years and the drug has been shown to continue to work during long-term treatment. Even though you take Doxazosin Tablets and it may help you, Doxazosin Tablets may not prevent the need for surgery in the future. 
  * Doxazosin Tablets do not affect PSA levels. PSA is the abbreviation for Prostate Specific Antigen. Your doctor may have done a blood test called PSA. You may want to ask your doctor more about this if you have had a PSA test done.
Directions for the Use of 2 mg, 1 mg, and 0.5 mg ATROPEN

  1. Snap the grooved end of the plastic sleeve down and over the Yellow Safety Release. Remove the ATROPEN autoinjector from the plastic sleeve. Do not place fingers on the Green Tip. 
  2. Firmly grasp the ATROPEN autoinjector with the Green Tip (needle end) pointed down. 
  3. With your other hand, pull off the Yellow Safety Release. ATROPEN is now ready to be administered. 
  4. Aim and firmly jab the Green Tip straight down (at a 90° angle) against the mid-lateral thigh. The ATROPEN device will activate and deliver the medicine when you do this. ATROPEN can inject through clothing, but make sure pockets at the injection site are empty. Very thin people and small children should also be injected in the mid-lateral thigh, but before giving ATROPEN, bunch up the thigh to provide a thicker area for injection. 
  5. Hold the ATROPEN autoinjector firmly in place for at least 10 seconds to allow the injection to finish. 
  6. Remove the ATROPEN autoinjector and massage the injection site for several seconds. If the needle is not visible, check to be sure the Yellow Safety Release has been removed, and repeat steps 4 and 5, but press harder. 
  7. After use, using a hard surface, bend the needle back against the ATROPEN autoinjector and either pin the used ATROPEN autoinjectors to the patient's clothing or show the used ATROPEN autoinjectors to the first medical person you see. This will allow medical personnel to see the number and dose of ATROPEN autoinjectors administered. Move yourself and the patient away from the contaminated area right away. Try to find medical help. 



Directions for the Use of 0.25 mg ATROPEN

  1. Remove the plastic cap from the yellow tube and slide the ATROPEN autoinjector from the tube. Do not place fingers on the Black Tip. 
  2. Firmly grasp the ATROPEN autoinjector with the Black Tip (needle end) pointed down. 
  3. With your other hand, pull off the Gray Safety Release. ATROPEN is now ready to be administered. 
  4. Bunch up the thigh to provide a thicker area for injection. Aim and firmly jab the Black Tip straight down (at a 90° angle) against the mid-lateral thigh. The ATROPEN device will activate and deliver the medicine when you do this. 
  5. Hold the ATROPEN autoinjector firmly in place for at least 10 seconds to allow the injection to finish. 
  6. Remove the ATROPEN autoinjector and massage the injection site for several seconds. If the needle is not visible, check to be sure the Gray Safety Release has been removed, and repeat steps 4 and 5, but press harder. 
  7. After use, using a hard surface, bend the needle back against the ATROPEN autoinjector and either pin the used ATROPEN autoinjectors to the patient's clothing or show the used ATROPEN autoinjectors to the first medical person you see. This will allow medical personnel to see the number and dose of ATROPEN autoinjectors administered. Move yourself and the patient away from the contaminated area right away. Try to find medical help.
BACKGROUND: Periodic repolarization dynamics (PRD) is an electrocardiographic biomarker that captures repolarization instability in the low frequency spectrum and is believed to estimate the sympathetic effect on the ventricular myocardium. High PRD indicates an increased risk for postischemic sudden cardiac death (SCD). However, a direct link between PRD and proarrhythmogenic autonomic remodeling has not yet been shown.
METHODS AND RESULTS: We investigated autonomic remodeling in pigs with myocardial infarction (MI)-related ischemic heart failure induced by balloon occlusion of the left anterior descending artery (n=17) compared with pigs without MI (n=11). Thirty days after MI, pigs demonstrated enhanced sympathetic innervation in the infarct area, border zone, and remote left ventricle paralleled by altered expression of autonomic marker genes/proteins. PRD was enhanced 30 days after MI compared with baseline (pre-MI versus post-MI: 1.75±0.30 deg2 versus 3.29±0.79 deg2, P<0.05) reflecting pronounced autonomic alterations on the level of the ventricular myocardium. Pigs with MI-related ventricular fibrillation and SCD had significantly higher pre-MI PRD than pigs without tachyarrhythmias, suggesting a potential role for PRD as a predictive biomarker for ischemia-related arrhythmias (no ventricular fibrillation versus ventricular fibrillation: 1.50±0.39 deg2 versus 3.18±0.53 deg2 [P<0.05]; no SCD versus SCD: 1.67±0.32 deg2 versus 3.91±0.63 deg2 [P<0.01]).
CONCLUSIONS: We demonstrate that ischemic heart failure leads to significant proarrhythmogenic autonomic remodeling. The concomitant elevation of PRD levels in pigs with ischemic heart failure and pigs with MI-related ventricular fibrillation/SCD suggests PRD as a biomarker for autonomic remodeling and as a potential predictive biomarker for ventricular arrhythmias/survival in the context of MI.
An on-demand and real-time evidence based cost modeling and predictive analysis system, and a financial incentives based plan to reduce healthcare costs. An analytics system that includes a data aggregator and regression models generates incremental expenditures among overweight and obese individuals, predictive forecasts of future medical costs, and predictive forecasts of cost reduction based on financial incentives to recipients. The forecasts may include interactions, personalized variables, statistical trends, prevalence of diseases based on body mass index and/or age, and medical evidence associated with specific illnesses. A computer-based program may process and analyze variables in healthcare records. A health insurance provider may provide an annual rebate on paid premiums to recipients based on a qualifying annual BMI as an incentive. The recipients may receive the rebates in a qualified Healthcare Individual Reimbursement Account (HIRA) managed by the recipients towards future healthcare related expenditures.
Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of Cognitive Behavioral Therapy for Eating Disorders.
Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
<P>PROBLEM TO BE SOLVED: To provide a calcium phosphate composition with its hardening time within an appropriate range and with an excellent marginal sealing property, the hardening time being the time necessary for the composition to harden after a medical solution is applied to the composition to be used in clinical practice.  <P>SOLUTION: The calcium phosphate composition includes calcium phosphate particles (A) and polyphosphate 300-50,000 molecular weight or the salt (F) thereof. The calcium phosphate composition includes 0.5-30 pts.wt. of polyphosphate or the salt (F) thereof based on 100 pts.wt. of calcium phosphate particles (A).  <P>COPYRIGHT: (C)2009,JPO&INPIT
In the forearm, posttraumatic heterotopic ossification usually forms as a proximal radioulnar synostosis. It can occur after soft tissue injury involving the interosseous membrane or after surgery involving the radio and ulna, such as distal biceps tendon repair. It can also be induced by radial head dislocation or fracture. Screening radiography can be used to select the appropriate time for excision. The synostosis can be resected when the ectopic bone margin and trabeculation appear mature on radiographs. An interval of 6-12 months from the injury is generally recommended based on ectopic bone maturity. Selection of the surgical approach depends on site, extension (elbow joint or proximal radioulnar joint), severity of the initial articular surface, and periarticular tissue injury. The posterolateral approach is indicated for synostoses: at or distal to the bicipital tuberosity, at the level of the radial head, and proximal radioulnar joint. The posterior global approach is recommended when the forearm synostosis is associated with complete bony ankylosis of the elbow involving the distal aspect of the humerus. After surgical resection of a proximal radioulnar synostosis, the exposed bone surfaces can be covered with interposition material to minimize recurrence.
A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
The subjects will attend for supervised training three sessions per week for 10 weeks (9-12). The strength training program involves dynamic contraction at intensities of 60 - 70 % of 1 repetition maximum (RM) to improve strength and muscle hypertrophy. Each session will contain 8 exercises on the major muscle groups. Each drill consists of 10-12 repetitions (reps) x 3 sets separated by one minute rest between sets.
While the exact healthbot features will be based on results from the rapid review, interviews and Wizard of OZ testing, the investigators know from the existing literature on medication adherence, and behaviour change interventions, that the healthbot will provide: 1) reminders for varenicline dosing and schedule; 2) information and suggestions on managing known side effects (the most frequently cited reason for varenicline non-adherence is experiencing side effects); 3) answers to questions about medication use (e.g., what to do if a dose is missed); and 4) support to increase participants' motivation to continue their quit attempts. During the next 12 weeks, participants will be reminded by the healthbot to take their varenicline at the appropriate times, and will be able to interact with the healthbot when they want.
A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum). Participants also receive technical smartphone coaching for the first 4 weeks of the study.
Schistosomiasis remains an important parasitic disease in the tropics, including Kenya. In the absence of a vaccine, the major control strategy is the reduction of morbidity by chemotherapy using Praziquantel. Evidence from laboratory studies and field trials continue to show that schistosome worms have developed reduced susceptibility to Praziquantel. These observations indicate the need for research to monitor the trends in efficacy of praziquantel and the need for research to develop novel antischistosomal drugs. Randomized controlled trials have also shown that Artemisinin derivatives (artesunate, artemether) have antischistosomal activity against S. mansoni, S. haematobium and S. japonicum. We propose to conduct an open-label, randomized trial to evaluate the comparative efficacy of artesunate plus sulfamethoxypyrazine-pyrimethamine versus Praziquantel in the treatment of 212 school children infected with S.mansoni in Rarieda district in western Kenya. To do this we will screen about 1000 school children by examination of stool for schistosome eggs. Eligible children will be randomized to receive either artesunate plus sulfamethoxypyrazine-pyrimethamine over 3 days or a single dose of Praziquantel. Four weeks after treatment, the participants will be assessed for cure and egg reduction.Our study may provide vital information regarding an alternative treatment for S. mansoni infection in children.
The present invention relates to a sheet mask containing fermented kimchi. A manufacturing method of the sheet mask comprises the steps of: mixing water and flour and heating the mixture; aging by adding kimchi fermentation materials to the heated mixture; removing the kimchi fermentation materials to manufacture natural cosmetic water; and adding a powder material to the natural cosmetic water. The kimchi fermentation materials include beets, garlic, and ginger in an amount of 150 to 180 parts by weight of garlic and 80 to 120 parts by weight of ginger relative to 100 parts by weight of the beets. The powder material is at least one selected from a group consisting of barley powder, lotus root powder, baekjiri powder, raw soybean powder, adlay powder, green tea powder, mung bean powder, rice bran powder, licorice powder, potato powder, white Wolfiporia extensa powder, malt powder, wheat flour, chestnut inner skin powder and apricot powder. Therefore, the sheet mask containing fermented kimchi effectively removes dead skin cells, sebum, wastes, grime, and the like, as well as melanin pigments generated by the sun, and thus improves skin regeneration ability, prevents the stratum corneum from thickening, and prevents blackheads or other skin problems caused by clogged pores. The sheet mask can also have antioxidant activity, anti-aging activity, and a regeneration effect of cells subjected to oxidative stress, and is safe and non-toxic to human skin by being made of natural raw materials.